A protein-based subunit vaccine with biological adjuvants provides effective protection against Pasteurella multocida in pigs

Table 4 Clinical and pathological analysis of pigs after challenge with P. multocida serotype A

Group	Total score^†	The score of gross lesions			Body weight (kg)
Group	Total score^†	Turbinate	Nasal septum	Lung	Total gain/11 days	Before challenge	After challenge
rPMT-NC + w/o/w + rSly	9^a	1	0	8	4.4 ± 1.3^ab	13.4 ± 3.8	17.7 ± 5.1
rPMT-NC + w/o/w + CpG	10^a	4	0	6	4.9 ± 1.7^ab	15.2 ± 1.6	20.1 ± 1.8
rPMT-NC	16^b	4	0	12	4.8 ± 3.3^ab	14.0 ± 4.6	18.8 ± 7.8
Commercial vaccine	18^b	6	1	11	5.3 ± 1.0^a	13.9 ± 1.8	17.2 ± 2.7
Control (PBS)	20^b	8	3	9	3.0 ± 1.1^b	11.6 ± 1.0	15.4 ± 1.5

^†Differences between groups compared to the controls using Duncan’s multiple comparison. A p value of < 0.05 was considered significant

ISSN: 1297-9716